Europe Proteomics Market Size, Growth, Share & Trends Analysis
Europe Proteomics Market by Instrumentation [Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray], Reagent (Immunoassay), Service (Purification, Bioinformatics), Software, Application (Clinical, Drug Discovery)- Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Europe proteomics market is projected to reach USD 18.77 billion by 2030 from USD 10.55 billion in 2025, at a CAGR of 12.2% from 2025 to 2030, enabled by the rapid advancements of mass spectrometry, bioinformatics, and high-throughput processing platforms. Proteomics primarily involves the analysis of the dynamic level of protein expression, modifications, and interactions in a bid to understand disease and response to therapies in oncology, neurology, and other complex diseases.
KEY TAKEAWAYS
-
BY COUNTRYGermany is projected to be the fastest-growing proteomics market, with a 13.4% CAGR during the forecast period.
-
BY INTRUMENTATIONBy product, the spectroscopy segment is expected to dominate the market.
-
BY REAGENTBy reagent, the immunoassay reagent segment is projected to grow at the fastest rate from 2025 to 2030.
-
BY SERVICEBy service, core proteomics services dominate the North American proteomics market.
-
BY SOFTWAREBy software, the bioinformatics tools segment is expected to dominate the market.
-
BY APPLICATIONBy application, the clinical diagnostics segment will grow the fastest during the forecast period.
-
BY END USERBy end user, the biopharmaceutical companies segment is expected to dominate the market.
-
COMPETITIVE LANDSCAPEThermofisher Scientific Inc (US), Merck KGaA (Germany), and Agilent Technologies (US) were identified as some of the star players in the Europe proteomics market, given their strong market share and product footprint.
-
COMPETITIVE LANDSCAPEMSAID GmbH(Germany) and Pixelgen Technologies AB(Sweden), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The European proteomics market is growing at a steady pace due to significant research funding, public-private partnerships, OldData programs, and the increasing application of proteomics in clinical decision-making. Modern proteomics platforms assist scientists and clinicians better understand disease biology, identify novel drug targets, and develop targeted treatments.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The Europe proteomics market is undergoing rapid transformation driven by accelerating scientific, regulatory, and clinical developments, with these dynamics expected to intensify through the forecast period. The increasing adoption of proteomics in precision oncology, cardiology, and other complex diseases, alongside robust progress in clinical trials, is fueling demand for high-throughput, reliable platforms across hospitals and research institutions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Continuous improvements and technological advancements
-
Aging population and rising chronic disease burden in Europe
Level
-
High cost of advanced proteomics technologies
Level
-
Expansion of multi-omics and clinical proteomics applications
Level
-
Slow clinical translation and reimbursement
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver:Continuous improvements and technological advancements
Continuous development and improvement in high-resolution mass spectrometry, next-generation sequencing integration, spatial proteomics, and bioinformatic procedures are improving analytical depth and reliability, they are enabling further development of proteomics technologies is important to make the field more applicable to research and clinical use.
Restraint: High cost of advanced proteomics technologies
High costs of advanced proteomics technologies and reagents limit accessibility for smaller institutions. Shortages of skilled professionals and complex data analysis requirements also hinder broader implementation.
Opportunity: Expansion of multi-omics and clinical proteomics applications
Expansion of multi-omics applications integrating proteomics with genomics and metabolomics offers significant growth potential. Government funding, AI-driven bioinformatics, and clinical assay development in countries like Germany, UK, and France create avenues for innovation.
Challenge: Slow clinical translation and reimbursement
Poor clinical translation and slow reimbursement processes further delay Commercialization of proteomics tools presents regulatory hurdles and data Management complexities add further barriers to market penetration.
EUROPE PROTEOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Orbitrap-based mass spectrometers, LC-MS workflows used in large-scale biopharma discovery, CROs, and academic medical centers | Improves depth protein profiling, supports robust biomarker validation for precision medicine CROs, delivers sensitive, reproducible data quantitation |
 |
QIAcuity digital PCR and LC-MS systems for proteomics sample prep, NGS-integrated assays supporting biopharma and clinical research | Delivers structural insights, helping customers accelerate biomarker discovery, optimize biopharma development submissions |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The European proteomics market is closely connected by instrument manufacturers, bioinformatics companies, CROs, biopharma companies, and clinical laboratories. Instrument and analysis solution providers offer high-throughput tools, while CROs and core facilities execute research studies. Applying this collaborative strategy will allow hospitals and biopharma organizations to identify quality biomarkers more quickly for the development of proteomics-enabled precision medicine.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Europe proteomics Market, By instrumentation technology.
In 2024, mass spectrometry-based platforms accounted for the largest share of the proteomics market in Europe, due to its importance in identifying and quantifying proteins at a highly resolving format.
Europe proteomics Market, By Reagent
In 2024, immunoassay reagents comprised the dominant product segment in 2024 due to increasing requirements for targeted protein panels as well as biomarker validations based on high-throughput techniques in the pharmaceutical industry.
Europe proteomics Market, By service
Basic proteomics services have a major share of the market, as many biotechnology, pharma, and hospital labs are outsourcing the complex LC MS processes to specialized service labs due to the need for data quality.
Europe proteomics Market, By software
In 2024, the category of bioinformatics tools became the largest in the software segment, owing to an increasing requirement for sophisticated data analysis, visualization, and integration tools that aid in the analysis of complex proteomics data together with genomic and clinical data.
Europe proteomics Market, By application
By application, clinical diagnostics is anticipated to have the fastest growth rate, owing to the increasing adoption of proteomics signatures in hospitals and reference laboratories for early disease detection, therapeutic purposes, and monitoring of diseases, especially for cancers and other chronic diseases.
Europe proteomics Market, By End User
The biopharmaceutical industry advanced as the prime end-users in 2024 due to heavy investments made in target identification, lead optimization, as well as biomarker-based clinical trial stratification.
REGION
Germany to be fastest-growing region in the market during forecast period
In 2024, Germany was the largest European proteomics market, with the highest growth rate, driven by high investment in biomedical research and the growing number of proteomics center companies and CROs. The rapid adoption of the latest developments in proteomics across oncology, precision medicine, and translational research, fueled by government subsidies and the development of biobanks, has made Germany a prominent driving force in the wider European proteomics market.
EUROPE PROTEOMICS MARKET: COMPANY EVALUATION MATRIX
Thermo Fisher Scientific was the Star Player due to its extensive portfolio of mass spectrometry platforms, proteomics reagents, and integrated software solutions that are deeply embedded in workflows for pharmaceutical, CRO, and academic research. Eurofins Scientific was the emerging leader; it strengthened its position by expanding its portfolio of proteomics, bioanalytical, and multi-omics services to support targeted, translational, and regulatory-driven research programs. In addition, these players are surrounded by specialized proteomics and multi-omics companies that cater to niche applications and adopt flexible service models, thereby building competitive intensity that positions them for future market leadership.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- THERMOFISHER SCIENTIFIC INC (US)
- Merck KGaA (Germany)
- Qiagen (Netherlands)
- AGILENT TECHNOLOGIES (US)
- Brukers Corporation (US)
- BIO-RAD LABORATORIES (US)
- Eurofins (Luxembourg)
- Protagene (Germany)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 9.80 Billion |
| Market Forecast in 2030 (Value) | USD 18.77 Billion |
| Growth Rate | CAGR of 12.2% from 2025–2030 |
| Years Considered | 2023–2030 |
| Base Year | 2024 |
| Forecast Period | 2025–2030 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | Germany, UK, France, Switzerland, Italy, Spain, Rest of Europe |
WHAT IS IN IT FOR YOU: EUROPE PROTEOMICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Market structure & competitive intensity | Assessed fragmentation across Western, Northern, and Southern Europe, identifying dominant players, regional champions, and emerging local specialists in proteomics instrumentation, reagents, and services. | Helps clients benchmark competitive intensity by geography and identify white spaces for entry, partnerships, or acquisition. |
| Regulatory & compliance landscape | Analyzed the impact of EU IVDR, GDPR, and national reimbursement frameworks on proteomics-based diagnostics, data handling, and clinical research workflows. | Supports compliant market entry strategies and reduces regulatory risk for diagnostic and data-driven proteomics offerings. |
RECENT DEVELOPMENTS
- May 2024 : QIAGEN launched a new library preparation kit-QIAseq Multimodal DNA/RNA Library Kit-facilitating multiomic studies and advancing precision medicine.
- September 2023 : Eurofins Scientific and Olink Holding AB entered a strategic partnership to enhance proteomics research and boost precision medicine initiatives.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study involved four major activities in estimating the current size of the proteomics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. The top-down and other approaches were employed to estimate the complete market size (proteomics market size). After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the proteomics market. The secondary sources referred to for this research study include publications from government and private sources such as the Indian Pharmaceutical Association (IPA), the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organization (CDSCO), Indian Brand Equity Foundation (IBEF), European Medicines Agency (EMA), Global Cancer Observatory (GCO), American Chemical Society (ACS), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), Pharmaceutical Research and Manufacturers of America (PhRMA), and the World Journal of Pharmaceutical Sciences, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Journals, Expert Interviews, MarketsandMarkets Analysis. Secondary data was collected and analyzed to arrive at the overall size of the global proteomics market, which was then validated by primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
Europe Proteomics Market Size Estimation
A top-down approach was used to estimate and validate the total size of the proteomics market. This method was also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the total proteomics market size includes the following:
Data Triangulation
After arriving at the overall proteomics market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Proteomics is the complete evaluation of the structure and function of proteins to understand an organism’s nature. It is the systemic identification and characterization of proteins along with their sequence, abundance, post-translational modifications, interactions, activity, subcellular localization, and structure. The market study includes the assessment of various instruments, reagents, software, and services used in proteomics.
Key Stakeholders
- Life sciences instrumentation and reagent companies
- Pharmaceutical and biotechnology companies
- Proteomics database and software providers
- Proteomics service providers
- Research and consulting firms
- Academic medical centers
- Government research organizations
- Clinical research institutes
- Contract Research Organizations
Report Objectives
- To define, describe, and forecast the global proteomics market based on the instrumentation technologies, reagents, software & services, application, end-user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micro markets with respect to individual growth trends, future prospects, and contributions to the overall proteomics market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
- To strategically profile the key players and comprehensively analyze their product & service portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, collaborations, and R&D activities in the proteomics market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Geographic Analysis
- Further breakdown of the Rest of Europe proteomics market into respective countries
- Further breakdown of the Rest of Asia Pacific proteomics market into respective countries
- Further breakdown of the Rest of Latin America proteomics market into respective countries
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
- An additional five company profiles
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Europe Proteomics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Europe Proteomics Market